New Highs & Levels For CYTK

put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic cardiomyopathy.

“The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases, and favorable tolerability profile,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.

Looks like the 236 fib line - using lows from the major gap down - has been a pivot over the last year or so. CYTK tested that level on July 19th and bounced during the morning session. The big question is can it maintain this as a new support level or is it looking at another breakdown following this huge move?

"Thanks to these results, Cytokinetics expressed its anticipation of what its Phase 3 trial could bring to the table. Let’s put this into perspective. CYTK wasn’t any of the penny stocks that broke out last year. However, its valuation was a fraction of what it is today. Last October, CYTK stock was trading around $15 a share; more than 50% less than its value on July 19th. With that, attention is certainly on smaller biotech stocks right now."

Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech